γ-Secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers

Cancer Research

Volumn 67, Issue 17, 2007, Pages 8051-8057

  Konishi, Jun ^a   Kawaguchi, Keiko S ^a   Vo, Huan ^a   Haruki, Nobuhiro ^b   Gonzalez, Adriana ^a   Carbone, David P ^a   Dang, Thao P ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; JAGGED1; MRK 003; NOTCH3 RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR HEY 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOGRAFT;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CYCLIC S-OXIDES; DISEASE PROGRESSION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; THIADIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34548572895     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1022     Document Type: Article

References (31)

1. Weinmaster G, Kopan R. A garden of Notch-ly delights. Development 2006;133:3277-82.
2. Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGF α-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003;3:565-76.
3. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005;65:8690-7.
4. Yoo AS, Bais C, Greenwald I. Crosstalk between the EGFR and LIN-12/Notch pathways in C. elegans vulval development. Science 2004;303:663-6.
5. Dang TP, Eichenberger S, Gonzalez A, Olson S, Carbone DP. Constitutive activation of Notch3 inhibits terminal epithelial differentiation in lungs of transgenic mice. Oncogene 2003;22:1988-97.
6. Dang TP, Gazdar AF, Virmani AK, et al. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 2000;92:1355-7.
7. Politi K, Feirt N, Kitajewski J. Notch in mammary gland development and breast cancer. Semin Cancer Biol 2004;14:341-7.
8. Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 2004;14:779-86.
9. Lopez-Nieva P, Santos J, Fernandez-Piqueras J. Defective expression of Notch1 and Notch2 in connection to alterations of c-Myc and Ikaros in γ-radiation-induced mouse thymic lymphomas. Carcinogenesis 2004;25:1299-304.
10. Hainaud P, Contreres JO, Villemain A, et al. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-Ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 2006;66:8501-10.
11. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003;3:756-67.
12. Collins BJ, Kleeberger W, Ball DW. Notch in lung development and lung cancer. Semin Cancer Biol 2004;14:357-64.
13. Haruki N, Kawaguchi KS, Eichenberger S, et al. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res 2005;65:3555-61.
14. Das I, Craig C, Funahashi Y, et al. Notch oncoproteins depend on γ-secretase/presenilin activity for processing and function. J Biol Chem 2004;279:30771-80.
15. Takasugi N, Tomita T, Hayashi I, et al. The role of presenilin cofactors in the γ-secretase complex. Nature 2003;422:438-41.
16. Koo EH, Kopan R. Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nat Med 2004;10 Suppl:S26-33.
17. Qin JZ, Stennett L, Bacon P, et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 2004;3:895-902.
18. Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ, Foreman KE. γ-Secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 2005;24:6333-44.
19. Alves da Costa C, Ayral E, Hernandez JF, St George-Hyslop P, Checler F. Presenilin-directed inhibitors of γ-secretase trigger caspase 3 activation in presenilin-expressing and presenilin-deficient cells. J Neurochem 2004;90:800-6.
20. Lewis HD, Leveridge M, Strack PR, et al. Apoptosis in Tcell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol 2007;14:209-19.
21. Paris D, Quadros A, Patel N, DelleDonne A, Humphrey J, Mullan M. Inhibition of angiogenesis and tumor growth by β- and γ-secretase inhibitors. Eur J Pharmacol 2005;514:1-15.
22. Krop IE, Kosh M, Fearen I, et al. Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. J Clin Oncol (Meeting Abstracts) 2006;24:10574.
23. Deangelo DJ, Stone RM, Silverman LB, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol (Meeting Abstracts) 2006;24:6585.
24. Dexter DL, Matook GM, Meitner PA, et al. Establishment and characterization of two human pancreatic cancer cell lines tumorigenic in athymic mice. Cancer Res 1982;42:2705-14.
25. Alves da Costa C, Paitel E, Mattson MP, et al. Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons. Proc Natl Acad Sci U S A 2002;99:4043-8.
26. Bellavia D, Campese AF, Alesse E, et al. Constitutive activation of NF-κB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 2000;19:3337-48.
27. Oswald F, Liptay S, Adler G, Schmid RM. NF-κB2 is a putative target gene of activated Notch-1 via RBP-Jκ. Mol Cell Biol 1998;18:2077-88.
28. Ni CY, Murphy MP, Golde TE, Carpenter G. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001;294:2179-81.
29. Lammich S, Okochi M, Takeda M, et al. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Aβ-like peptide. J Biol Chem 2002;277:44754-9.
30. Dalrymple S, Antony L, Xu Y, et al. Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res 2005;65:9269-79.
31. Dovey HF, John V, Anderson JP, et al. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J Neurochem 2001;76:173-81.